In Brief: Taro
This article was originally published in The Tan Sheet
Taro: Receives U.S. approval of ANDA for 2% miconazole nitrate vaginal cream through its subsidiary, Taro Pharmaceuticals, Inc. of Ontario, Canada. The cream, which is equivalent to Ortho's Monistat-7, will be available for private label sale within two months and also will retail under the Taro name...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC